Halozyme Therapeutics Inc...

NASDAQ: HALO · Real-Time Price · USD
67.05
1.51 (2.30%)
At close: Aug 15, 2025, 1:28 PM

Halozyme Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
115.85M 118.37M 234.19M 118.72M
Short-Term Investments
480.22M 217.63M 128.6M 622.2M
Long-Term Investments
n/a n/a 500K 500K
Other Long-Term Assets
80.6M 17.82M 26.3M 13.91M
Receivables
308.45M 234.21M 231.07M 90.97M
Inventory
141.86M 127.6M 100.12M 53.91M
Other Current Assets
38.95M 48.61M 45.02M 40.48M
Total Current Assets
1.09B 746.42M 739.01M 926.29M
Property-Plant & Equipment
75.03M 74.94M 75.57M 8.79M
Goodwill & Intangibles
818.65M 889.7M 955.7M -500K
Total Long-Term Assets
978.14M 986.85M 1.1B 178.14M
Total Assets
2.06B 1.73B 1.84B 1.1B
Account Payables
10.25M 11.82M 17.69M 1.54M
Deferred Revenue
n/a n/a 3.25M 1.75M
Short-Term Debt
n/a n/a 13.33M 89.42M
Other Current Liabilities
128.85M n/a -1.14M 2.28M
Total Current Liabilities
139.1M 112.49M 130.79M 117.15M
Long-Term Debt
1.51B 1.5B 1.49B 787.25M
Other Long-Term Liabilities
54.76M 37.72M 13.22M n/a
Total Long-Term Liabilities
1.56B 1.54B 1.54B 790.33M
Total Liabilities
1.7B 1.65B 1.67B 907.48M
Total Debt
1.51B 1.5B 1.51B 876.67M
Common Stock
123K 127K 135K 138K
Retained Earnings
359.87M 90.55M 143.22M -58.91M
Comprehensive Income
3.83M -9.28M -922K -620K
Shareholders Equity
363.82M 83.81M 169.8M 196.95M
Total Investments
480.22M 217.63M 128.6M 622.2M